A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma

Cancer

Volumn 82, Issue 3, 1998, Pages 503-511

  Morrell, Louise E ^a   Lee, Young J ^b,d   Hurley, Judith ^b   Arias, Mayda ^c   Mies, Carolyn ^b   Richman, Stephen P ^b   Fernandez, Hugo ^b   Donofrio, Kim A ^c   Raub Jr , William A ^b   Cassileth, Peter A ^b  

^a Boca Raton Community Hospital   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Sylvester Compreh Cancer Center ^*  (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

Breast carcinoma; Locally advanced breast carcinoma; Methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC); Neoadjuvant chemotherapy; Primary chemotherapy

Indexed keywords

CISPLATIN; DOXORUBICIN; FOLINATE CALCIUM; METHOTREXATE; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; VINBLASTINE;

EID: 0032005320     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980201)82:3<503::AID-CNCR12>3.0.CO;2-5     Document Type: Article

References (39)

1. Hortobagyi GN, Blumenschein GR, Spanos W, Montagu ED, Buzdar AU, Yap HY, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983;51:763-8.
2. Beahrs OH, Henson DE, Hutter RV, Kennedy BJ. Manual for staging of cancer. 4th edition. Philadelphia: J.B. Lippincott, 1993: 161-7.
3. Haagensen CD, Stout AP. Carcinoma of the breast. II. Criteria of operability. Ann Surg 1943;118:859-70,1032-51.
4. Bruckman JE, Harris JR, Leneve MB, Chaffey JT, Hellman S. Results of treating stage III carcinoma of the breast by primary radiation therapy. Cancer 1979;43:985-94.
5. Sorace RA, Lippman ME. Locally advanced breast cancer. In: Lippman ME, Lichter AS, Danforth DN, editors. Diagnosis and management of breast cancer. Philadelphia: W. B. Saunders, 1988: 272-95.
6. Bonnadonna G. Conceptual and practical advances in the management of breast cancer. Karnofsky Memorial Lecture. J Clin Oncol 1989;7:1380-97.
7. DeLena M, Zucale R, Viganotti G, Valagussa P, Bonnadonna G. Combined chemotherapy-radiation therapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978;1:53-9.
8. DeLena M, Varini M, Zucali R, Rovini D, Viganotti G, Valagussa P, et al. Multimodal treatment for locally advanced breast cancer: results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 1981;4:229-36.
9. Swain SM, Sorace RA, Bagley CS, Danforth DN, Bader J, Wesley MN, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced non-metastatic breast cancer. Cancer Res 1987;47:3889-94.
10. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1994;74:416-23.
11. Kolaric K, Roth A. Phase II clinical trial of cis-dichlorodiominine platinum (Cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983;11:108-12.
12. Sledge GW, Roth BJ. Cisplatin in the management of breast cancer. Semin Oncol 1989;16(Suppl 6):100-5.
13. Sledge GW, Loehrer PJ, Roth BJ, Einhorn LH. Cisplatin at first-time therapy for metastatic breast cancer. J Clin Oncol 1988;6:1811-4.
14. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1049 cases of which 359 have been followed 15 years. Br J Cancer 1957;11:359-77.
15. Elston CW, Ellis IO. Pathologic prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term followup. Histopathology 1991;19:403-10.
16. Page DL, Ellis IO, Elston CW. Histologic grading of breast cancer. Am J Clin Pathol 1995;103:123-4.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, Inc., 1980.
19. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972;834:187-220.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
21. Calais G, Descamps P, Chapet S, Turgeon V, Reynaud-Bournoux A, Lamarie E, et al. Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers. Int J Radiat Oncol Biol Phys 1993;26:37-42.
22. Gardin G, Rosso R, Campora E, Repetto L, Naso C, Canavese G, et al. Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogenously treated with a combined modality approach. Eur J Cancer 1995;31A:1428-33.
23. Kudelka A, Abel W, Berken A, Fiore J, Schubach W, Viola M, et al. Phase II trial of methotrexate, vinblastine, doxorubicin, cisplatin and folinic acid (MVAC/FA) in the treatment of locally advanced and metastatic breast cancer: an update [Abstract 194]. Proc Am Soc Clin Oncol 1989;8:50.
24. Cocconi G, Anastasis P, Bella M, Carpi A, Colozza M, Indelli M, et al. Front-line CMF compared to a short chemotherapy with MVAC-like cisplatin containing combination in metastatic breast carcinoma [Abstract 136]. Proc Am Soc Clin Oncol 1995;14:109.
25. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13:424-9.
26. Balawajder I, Antich PP, Boland J. An analysis of the role of radiotherapy alone and in combination with chemotherapy and surgery in the management of advanced breast carcinoma. Cancer 1983;51:574-80.
27. Jacquillat C, Baillet F, Weil M, Auclerc G, Housset M, Auclerc MF, et al. Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB). Cancer 1988;61:1977-82.
28. Bonadonna G, Veronesi U, Brambila C, Ferrari L, Greco M, Bartoli C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;82:1539-45.
29. Scholl SM, Fourquet A, Asselain B, Pierga, JY, Vilcoq JR, Durand JC, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomized trial, S6. Eur J Cancer 1994;30A:645-52.
30. Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G, Maublanc MA, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990;66:119-29.
31. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 1988;62:2507-16.
32. Smith IE, Jones AL, O'Brien ME, McKinna JA, Sacks N, Baum M. Primary medical (neoadjuvant) chemotherapy for operable breast cancer. Eur J Cancer 1993;29A:1796-9.
33. Bedwinek J, Rao DV, Perez C, Lee J, Finberg B. Stage III and localized stage IV breast cancer: irradiation alone versus irradiation plus surgery. Int J Radiat Oncol Biol Phys 1982;8:31-6.
34. Scholl SM, Asselain B, Palagie T, Dorval T, Jouve M, Garcia-Giralt E, et al. Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 1991;27:1668-71.
35. Scholl SM, Pierga JY, Asselain B, Beuzeboc P, Dorval T, Garcia-Giralt E, et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 1995;31A:1969-75.
36. Botti C, Vici P, Lopez M, Scinto AF, Cognetti F, Cavaliere R. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg 1995;181:202-8.
37. Touboul E, Buffat L, Lefranc JP, Blondon J, Deniaud E, Mammar H, et al. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced non-inflammatory breast cancer. Int J Radiat Oncol Biol Phys 1996;34:1019-28.
38. Veronesi U, Bonadonna G, Zurrida S, Galimberti V, Greco M, Brambilla G, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995;222:612-8.
39. McCready DR, Hortobagyi GN, Kau SW, et al. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 1989;124:21-5.